METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF CILNIDIPINE AND OLMESARTAN MEDOXOMIL IN TABLET DOSAGE FORM BY UPLC USING DAD

Olmesartan Medoxomil and Cilnidipine combination lowers blood pressure effectively. Olmesartan Medoxomil is an angiotensin receptor blocker (ARB), and Cilnidipine is a calcium channel blocker (CCB). Cilnidipine and Olmesartan Medoxomil are widely used in hypertension. The scope of the study is to optimize the chromatographic conditions to develop a new RP-UPLC method for the simultaneous estimation of Olmesartan Medoxomil and Clinidipine, which is simple, accurate, precise, and rapid. A very few methods were developed by UPLC using DAD. The mobile phase used is 0.5% w/v Ammonium acetate buffer: methanol: Acetonitrile (40:50:10), and the detection was carried out at 240 nm by using PDA detector. The flow rate was optimized at 0.4ml/min. The retention time was found to be 0.587 and 0.992 for Olmesartan Medoxomil and Cilnidipine, respectively. All the parameters of the method development and validation meet the ICH guidelines criteria. Thus the work establishes that the reported method is more economical and can be regularly used in practical application for simultaneous analysis of the Cilnidipine (CIL) and Olmesartan medoxomil (OLME) in their combined dosage forms both in research and quality control laboratories.